Connection

JENNIFER FOSTER to Neoplasms

This is a "connection" page, showing publications JENNIFER FOSTER has written about Neoplasms.
Connection Strength

1.175
  1. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
    View in: PubMed
    Score: 0.326
  2. Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy. J Oncol Pharm Pract. 2022 Jun; 28(4):904-909.
    View in: PubMed
    Score: 0.275
  3. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. Pediatr Blood Cancer. 2021 03; 68(3):e28871.
    View in: PubMed
    Score: 0.254
  4. Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
    View in: PubMed
    Score: 0.085
  5. Real-World Experience Using Sodium Thiosulfate Pentahydrate Off-Label for Cisplatin Otoprotection in Children, Adolescents, and Young Adults. Pediatr Blood Cancer. 2025 May; 72(5):e31631.
    View in: PubMed
    Score: 0.085
  6. Indications and Outcomes for Tracheostomies in Pediatric Oncology Patients-A Single Center Study. Pediatr Blood Cancer. 2025 Feb; 72(2):e31451.
    View in: PubMed
    Score: 0.083
  7. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021 Oct 01; 7(10):1550-1558.
    View in: PubMed
    Score: 0.067
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.